Taysha Gene Therapies, Inc. — Income Charts
2 years of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue
$10M
R&D
$86M
D&A
$1M
Operating Income
$-110M
EBITDA
$-109M
Interest Expense
$63K
Interest Income
$9M
Tax Provision
$0
Net Income
$-109M
Operating Margin
-1130.6%
Net Margin
-1115.3%
Deferred Tax Liabilities
$3M
DTA Valuation Allowance
$138M
Tax Credit Carryforwards
$14M
NOL Carryforwards
$218M
ETR (Continuing Operations)
0.0%
ETR Federal Statutory
21.0%
ETR State + Local (pp)
-0.0%
Operating Lease Cost
$3M
Revenue YoY Variation
17.3%
Income YoY Variation
-20.8%